Jiashitang 2025 Annual Report Interpretation: Operating Cash Flow Increased 671.92% Net Profit Decreased 29.57%

MaticHoleFiller · 2026-03-20T22:00:21+00:00

In 2025, Jiashitang's operating revenue and net profit both declined significantly, reaching 195.25 billion yuan and 111 million yuan, respectively. The company demonstrated good cost control performance, with period expenses decreasing by 32.13%. Operating cash flow improved substantially; however, the company faces multiple risks including policy changes and intensifying market competition. Executive compensation shows range differentiation, and overall compensation is not fully synchronized with business performance.

MaticHoleFiller

2026-03-20 22:00:21

Abstract generation in progress

Core Profitability Metrics Analysis

Operating Revenue: Shrinks by Over 4.5 Billion, Multiple Sectors Decline

In 2025, Jiashitang achieved an operating revenue of 19.525 billion yuan, down 18.71% from 24.019 billion yuan in 2024, a decrease of approximately 4.494 billion yuan. By business segment, the pharmaceutical wholesale business, accounting for 96.32% of total revenue, generated 18.806 billion yuan, down 16.79%; pharmaceutical logistics revenue was 136 million yuan, a plunge of 69.13%; and pharmacy chain revenue was 583 million yuan, down 40.35%. Regionally, revenue from other areas was 9.189 billion yuan, a significant drop of 29.41%, mainly dragging down overall revenue.

Net Profit: Net Profit Attributable to Shareholders Falls Below 120 Million, Profitability Under Pressure

Net profit attributable to shareholders was 111 million yuan, a sharp decline of 29.57% from 158 million yuan in 2024 (adjusted). Net profit excluding non-recurring gains and losses was 92 million yuan, up 14.55%. Non-recurring gains and losses totaled 19.5 million yuan, mainly from government subsidies and asset disposals. The growth in non-recurring net profit indicates the company’s core business profitability remains resilient, but the overall net profit decline reflects a significant shrinkage in non-recurring income (779 million yuan in 2024).

Earnings Per Share: Basic EPS Drops to 0.38 Yuan

Basic earnings per share were 0.38 yuan, down 29.63% from 0.54 yuan in 2024; adjusted EPS was 0.31 yuan, up 14.81% from 0.27 yuan. The trend aligns with the change in net profit excluding non-recurring items, indicating improved profitability after removing one-time gains and losses.

Cost Control: Multiple Dimensions Reduced, Expense Ratios Improved Against the Trend

In 2025, the company’s total operating expenses were 678 million yuan, down 32.13% from 999 million yuan in 2024, demonstrating effective cost management:

Expense Item	2025 (10,000 yuan)	2024 (10,000 yuan)	YoY Change	Reason for Change
Selling Expenses	2,615.646	5,188.859	-49.59%	Revenue decline, reduced personnel and marketing expenses
Management Expenses	2,717.191	3,638.972	-25.33%	Lower management personnel costs and depreciation
Financial Expenses	743.576	1,179.960	-36.98%	Reduced bank loans and financing costs

The significant reduction in selling expenses is a key highlight, with marketing costs dropping from 79.88 million yuan in 2024 to 11.99 million yuan, an 84.98% decrease, directly lowering the expense ratio from 2.16% to 1.34%.

R&D Investment: No Disclosure of R&D Expenses, R&D Resources Unclear

During the reporting period, the company did not disclose R&D expenses or specific R&D personnel information. R&D investment details are absent, and the company’s technological upgrades and digital transformation efforts in the pharmaceutical distribution sector remain unclear.

Cash Flow: Operating Cash Flow Surges, Investment and Financing Cash Flows Contract

In 2025, the company’s cash flow shows an “one increase, two decreases” pattern:

Cash Flow Item	2025 (10,000 yuan)	2024 (10,000 yuan)	YoY Change	Reason for Change
Operating Cash Flow	1,392.1965	180.3552	671.92%	Strengthened receivables collection, increased cash inflow from sales, wider gap between receivables and payables; impairment provisions impact net profit but not cash flow; cash outflows for sales and admin expenses as a percentage of revenue decreased
Investing Cash Flow	-573.80	36,800.32	-101.56%	Last year, disposal of fixed assets by subsidiaries generated large cash inflows; this year, no such large disposals
Financing Cash Flow	-1,053.0883	-904.7098	-16.40%	Reduced external financing, increased debt repayment

The significant improvement in operating cash flow is a core highlight, achieved through strengthened receivables management and optimized expense payments, markedly enhancing cash flow quality.

Risk Warning: Operating Challenges Under Multiple Pressures

During the reporting period, the company faces multiple risks:

Industry Policy Risks: Volume-based procurement and healthcare policy adjustments continue to compress profit margins in the pharmaceutical distribution chain, impacting device and retail businesses.
Market Competition Risks: Industry concentration increases, intensifying competition among leading firms. The sharp decline in regional revenue reflects competitive pressures.
Transformation Risks: The company is advancing business model transformation and digital upgrades, but results have yet to materialize, with risks of underperformance.
Control Rights Change Risks: In February 2026, the company’s shareholders will transfer shares to Tongrentang Group, with Beijing State-owned Assets Supervision and Administration Commission becoming the actual controller. This change may lead to strategic and management adjustments, bringing some uncertainties.

Executive Compensation: Core Executives’ Salary Range Diverges

During the period, the pre-tax salaries of key executives were:

Chairman Xu Xi: 1.0497 million yuan
President Huang Yibin: 1.3718 million yuan
Vice President Lin Jun: 950,000 yuan
Vice President Wang Peng: 886,500 yuan

The president’s salary is the highest among core executives, reflecting incentives for operational leadership. Overall, executive compensation does not fully align with company performance, warranting attention to the linkage between pay and results.

Click to view the original announcement>>

Disclaimer: The market involves risks; investment should be cautious. This article is automatically generated by an AI model based on third-party data and does not represent Sina Finance’s views. All information herein is for reference only and does not constitute personal investment advice. Please refer to official disclosures for accuracy. For questions, contact biz@staff.sina.com.cn.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.